Clinical Research Progress of Low-Dose Interleukin-2 in the Treatment of Chronic Spontaneous Urticaria

I. Introduction

Chronic spontaneous urticaria (CSU), as the most common clinical type of chronic urticaria, has a prevalence rate as high as 2.6% among adults in China. The disease is characterized by recurrent wheals accompanied by intense itching, with a protracted and difficult-to-treat course. Severe cases may even present with systemic symptoms such as nausea, vomiting, and dizziness, significantly impacting patients' physical and mental health as well as their quality of life. Currently, clinical treatment of CSU still faces numerous challenges, making the exploration of safe, effective, and economically accessible new therapeutic strategies of great clinical significance.

II. Clinical Features and Pathogenesis of CSU

(1) Clinical Manifestations and Disease Course Characteristics

CSU manifests as localized edema reactions caused by reactive dilation and increased permeability of small blood vessels in the skin and mucous membranes. Clinically, it primarily presents as wheals of varying sizes and/or angioedema, often accompanied by significant itching. Wheals may appear red, light pink, or pale in the central area, ranging from localized distribution to widespread fusion. The typical course of CSU lasts 2 to 5 years, with some patients experiencing symptoms for over 5 years. Therefore, once the duration exceeds 6 weeks, long-term disease management should be anticipated.

(2) Etiology and Immunological Mechanisms

The pathogenesis of CSU is complex, involving multiple factors such as autoimmunity, allergic factors, chronic infections, coagulation abnormalities, and psychological stress. From an immunological perspective, most CSU patients exhibit immune imbalances among different functional subsets of T lymphocytes, suggesting that the disease is essentially an abnormally activated immune response state rather than a simple immunodeficiency. This understanding provides a theoretical basis for exploring immune-modulating therapeutic strategies.

III. Current Treatment Status and Challenges of CSU

(1) Current Treatment Strategies and Their Limitations

Second-generation antihistamines are currently the internationally recognized first-line treatment for CSU. However, some patients exhibit poor responses to this therapy. Second- and third-line treatments primarily include biologics and immunosuppressants such as cyclosporine. The former is prohibitively expensive, while the latter carries significant toxic side effects. Therefore, there is an urgent clinical need to explore a new therapeutic strategy that is safe, effective, and economically accessible.

(2) Unmet Clinical Needs

For refractory CSU patients who respond poorly to first-line treatments, current therapeutic options are limited. How to effectively control symptoms while reducing treatment costs and minimizing adverse reactions has become a critical issue in the field of CSU treatment.

IV. Innovative Strategy of Low-Dose IL-2 Therapy

(1) Immunomodulatory Properties of IL-2

Interleukin-2 (IL-2) is a T-cell cytokine with bidirectional immunomodulatory effects. In recent years, low-dose IL-2 therapy has shown promising efficacy in various autoimmune diseases. Based on preliminary findings of T-cell immune imbalances in CSU patients, researchers have proposed using low-dose IL-2 as an immunomodulatory strategy to restore immune homeostasis and control disease activity.

(2) Optimization of Dosing Regimen

Through continuous clinical exploration and regimen refinement, the research team has gradually established an optimized "seven-day therapy" dosing regimen, involving consecutive daily injections of low-dose IL-2 for seven days. This regimen aims to rapidly reestablish immune balance through short-term intensive dosing while minimizing adverse effects. In related mechanistic studies, the Mouse IL-2 Kit (HICA) can be used to detect IL-2 levels in animal models, providing an essential tool for preclinical mechanism validation and dosing strategy optimization.

V. Research Significance and Future Perspectives

(1) Clinical Value

This study offers an effective, safe, and economically accessible new treatment option for CSU patients who respond poorly to antihistamine therapy. Compared to traditional second- and third-line treatments, this regimen significantly reduces treatment costs, alleviating the financial burden on patients and demonstrating substantial clinical value for widespread adoption.

(2) Need for Mechanistic Research

Although preliminary clinical efficacy is encouraging, the molecular mechanisms underlying low-dose IL-2 therapy for CSU remain incompletely understood. Future research should delve into the key targets and signaling pathways through which IL-2 exerts its immunomodulatory effects, further optimizing the dosing regimen.

(3) Accumulation of Evidence-Based Medicine

Subsequent large-sample, multicenter randomized controlled clinical trials are needed to accumulate high-quality evidence-based medical data supporting the clinical application of low-dose IL-2 therapy for CSU. During this process, detection tools such as the Mouse IL-2 Kit (HICA) will continue to play a supportive role in mechanistic research and biomarker exploration.

VI. Which Manufacturers Provide Mouse IL-2 Kit (HICA)?

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "Mouse IL-2 Kit (HICA)", a high-performance analysis platform specifically designed for studying key pathways of T-cell activation and immune regulation in mice. This kit aims to accurately and efficiently quantify the immune-binding activity of mouse interleukin-2 (IL-2) protein, providing stable and reliable standardized solutions for mechanism research and preclinical drug efficacy evaluation in fields such as tumor immunology, autoimmune diseases, transplantation immunology, and more.

Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "Mouse IL-2 Kit (HICA)" (Catalog No.: UA086050), please feel free to contact us at any time.